Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease

Hepatology

The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis

J Gastroenterol Hepatol.

Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A

doi: 10.1111/jgh.14867.

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

HepatitisHepatology

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Lancet Gastroenterol Hepatol.

Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M

doi: 10.1016/S2468-1253

Hepatology

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

BMC Gastroenterol.

Liang Y, Li D

doi: 10.1186/s12876-020-01234-x.

Hepatology

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

BMC Gastroenterol.

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM

doi: 10.1186/s12876-020-01251-w.

Gastrointestinal CancerHepatology

Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes

Hepatology.

Natarajan Y, Kramer JR, Yu X, Li L, Thrift AP, El-Serag HB, Kanwal F

doi: 10.1002/hep.31157.

Hepatology

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

J Hepatol.

Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V

doi: 10.1016/j.jhep.2019.12.008.

Further Publications

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease

Clin Gastroenterol Hepatol

Kai Toh JZ, Pan XH, Lin Tay PW, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Xuan Tan EX, Dan YY, Loh PH, Foo R, Chew NW, Sanyal AJ, Muthiah MD, Siddiqui MS

doi: 10.1016/j.cgh.2021.09.021

Hepatology

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

BMC Gastroenterol

Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH

doi: 10.1186/s12876-021-01660-5

Related content

The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease

A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease